Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half effective dose of remimazolam toluenesulfonic acid combined with sufentanil for laryngeal mask placement in hysteroscopic electrotomy
ChiCTR2400079790Phase 4Recruiting
- Sponsor
- Nanchong City Central Hospital
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of remimazolam and sufentanil (2 arms), sponsored by Nanchong City Central Hospital. Primary endpoint: Median effective dose of remimazolam (ED50) to inhibit laryngeal mask insertion response. Started Jan 2024; status: recruiting.
02
Drugs
remimazolamsufentanil
Beyond the preview
Go deeper on ChiCTR2400079790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079790.